Skip to main content
SpringerLink
Log in

The Aims of Antipsychotic Medication

What Are They and Are They Being Achieved?

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Summary

The aims of therapy with antipsychotic medications include effecti ve relief of symptoms without the induction of adverse effects, improved quality of life and cost effectiveness, and positive long term outcomes. However, currently available anti psychotics do not meet all of these requirements due to a number of well recognised limitations, such as a marked variability of response, induction of a wide range of adverse effects and a lack of subjective tolerability.

A lack of response to antipsychotic medications occurs in up to 30% of patients and poses a particular challenge to clinicians. The reintroduction of clozapine for the treatment of patients with refractory schizophrenia has proven useful in a good number of patients, albeit with some risk of serious agranulocytosis and at a relatively high cost.

Despite the extensive use of anti psychotics over the last 4 decades, little attention has been paid to the systematic evaluation of quality of life in patients with schizophrenia who receive medications, and in clinical trials of new agents. Similarly, there is a dearth of studies that have examined the cost effectiveness and cost utility of anti psychotics in terms of quality of life.

In general, the aim of anti psychotics of alleviating psychotic symptoms without negatively affecting the functional status of patients has not been adequately, nor consistently, achieved with currently available agents. However, with the recent acceleration in the development of new antipsychotics, it is hoped that new drugs will soon be available which will prove to be more effective in treating more symptoms of schizophrenia and will be associated with fewer, or ideally no, adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davies LM, Drummond ME. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5

    Article  Google Scholar 

  2. Gunderson JG, Mosher LR. The cost of schizophrenia. Am J Psychiatry 1975; 132: 901–6

    PubMed  CAS  Google Scholar 

  3. Wyatt RJ. Cost and savings in schizophrenia. Presentation to the Third Workshop on Cost and Assessment in Psychiatry; 1994 Oct 28-30; Venice,Italy

    Google Scholar 

  4. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246–61

    Article  Google Scholar 

  5. Goldberg SC, Klerman GL, Cole JO. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. Br J Psychiatry 1965 111; 120–3

    Article  PubMed  CAS  Google Scholar 

  6. Cole JO, Klerman GL, Davies JM. Drugs in the treatment of psychosis in controlled studies. In: Solomon P, editor. Psychiatric drugs. New York: Grune and Stratton, 1966: 153–80

    Google Scholar 

  7. Davis JM, Schaffer CB, Killman GA, et al. Important issues in the treatment of schizophrenia. Schizophr Bull 1980; 6: 70–87

    PubMed  CAS  Google Scholar 

  8. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975; 132: 1237–45

    PubMed  CAS  Google Scholar 

  9. Leff JP, Wing JK. Trial maintenance therapy in schizophrenia. BMJ 1971; 2: 599–603

    Article  Google Scholar 

  10. Prien RF, Levine J, Switalsky RN. Discontinuation of chemotherapy for chronic schizophrenics. Hosp Community Psychiatry 1977; 22: 4–9

    Google Scholar 

  11. Awad AG. Drug therapy in schizophrenia — variability of outcome and prediction of response. Can J Psychiatry 1989; 34: 711–20

    PubMed  CAS  Google Scholar 

  12. Judd LL, Goldstein MJ, Rodnick EH, et al. Phenothiazine effects in good premorbid schizophrenics divided into paranoid- non paranoid status. Arch Gen Psychiatry 1973; 29: 207–11

    Article  PubMed  CAS  Google Scholar 

  13. Rappaport M, Hopkins KH, Hall K, et al. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry 1987; 13: 100–11

    Google Scholar 

  14. May PRA, Goldberg Sc. Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, Di Mascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 1135–9

    Google Scholar 

  15. Lydiard BR, Laird LK. Prediction of response to anti psychotics. J Clin Psychopharmacol 1988; 8: 3–13

    PubMed  CAS  Google Scholar 

  16. Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 1993; 16: 313–38

    PubMed  CAS  Google Scholar 

  17. Awad AG. Prediction research of neuroleptic treatment outcome in schizophrenia — state of the art: 1978-1993. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia - concepts and methods. Vienna: Springer-Verlag, 1994: 1–4

    Chapter  Google Scholar 

  18. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenics. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  19. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329–38

    PubMed  CAS  Google Scholar 

  20. Awad AG. There are real risks and benefits with clozapine in schizophrenia. Med North Am 1992; 4: 234–8

    Google Scholar 

  21. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bull 1993; 19: 609–18

    CAS  Google Scholar 

  22. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1978; 38: 187–90

    Article  Google Scholar 

  23. Hogan TP, Awad AG, Eastwood MR. Self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983; 13: 177–83

    Article  PubMed  CAS  Google Scholar 

  24. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347–52

    Article  PubMed  CAS  Google Scholar 

  25. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994; 89 Suppl. 380: 27–32

    Article  Google Scholar 

  26. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 3: 261–5

    Google Scholar 

  27. Awad AG. Quality of life in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Association Press, 1995: 883–46

    Google Scholar 

  28. Voruganti LNP, Heslegrave R, Awad AG. Schizophrenia, antipsychotic therapy and quality of life — validation of a conceptual model. Presentation to 33rd Annual Meeting of the American College of Neuropsychopharmacology; 1994 Dec 12-16

    Google Scholar 

  29. Schipper H, Clinch J, Powell V. Definition and conceptual issues. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 11–24

    Google Scholar 

  30. Davidhizar RE. Can clients with schizophrenia describe feelings and beliefs about taking medications. J Adv Nursing 1985; 10: 469–73

    Article  CAS  Google Scholar 

  31. Awad AG. Quality of life on neuroleptics - implications for health economics and drug trials in schizophrenia. Presentation to the Third Workshop on Cost and Assessment in Psychiatry; 1994 Oct 28-30; Venice

    Google Scholar 

  32. Skantze K, Maim U, Decker SJ, et al. Comparison of quality of life with standard of living in schizophrenia out-patients. Br J Psychiatry 1992; 161: 797–801

    Article  PubMed  CAS  Google Scholar 

  33. Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics 1993; 4: 131–56

    Article  PubMed  CAS  Google Scholar 

  34. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer H, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1103–9

    Google Scholar 

  35. Glick ID. Neuroleptic psychosocial interactions and prediction of outcome. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia. Vienna: Springer-Verlag, 1994: 65–70

    Chapter  Google Scholar 

  36. Glick ID, Spencer JH, Clarkin JF, et al. A randomized clinical trial of impatient family intervention: IV. Follow-up results for subjects with schizophrenia. Schizophr Res 1990; 3: 187–200

    Article  PubMed  CAS  Google Scholar 

  37. Schooler NR, Keith SJ, Severe JB, et al. Acute treatment response and short-term outcome in schizophrenia in first results of NIMH treatment strategies in schizophrenia study. Psychopharmacol Bull 1989; 25: 331–5

    PubMed  CAS  Google Scholar 

  38. Herz MI.Intermittent medication and schizophrenia. In: Kane JM, editor. Drug maintenance strategies in schizophrenia. Washington: American Psychiatric Association, 1984: 58–68

    Google Scholar 

  39. Carpenter WT, Heinricks OW, Hanlan TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144: 1466–70

    PubMed  Google Scholar 

  40. Gaebal W, Frick U, Kiipcke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 1993; 163 Suppl. 21: 8–21

    Google Scholar 

  41. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812

    Article  Google Scholar 

  42. Wing JK, Birley JLT, Cooper JE, et al. Reliability of a procedure for measuring and classifying present psychiatric state. Br J Psychiatry 1967; 113: 499–575

    Article  PubMed  CAS  Google Scholar 

  43. Andreason NC, Olsen SA. Negative versus positive schizophrenia, definition and validation. Arch Gen Psychiatry 1982; 39: 789–94

    Article  Google Scholar 

  44. Kay SR, Opler LA, Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76

    PubMed  CAS  Google Scholar 

  45. Awad AG. Methodological and design issues in clinical trials of new neuroleptics — an overview. Br J Psychiatry 1993; 163 Suppl. 22: 51–7

    Google Scholar 

  46. Snaith RP. Measurement in psychiatry. Br J Psychiatry 1991; 159: 78–82

    Article  PubMed  CAS  Google Scholar 

  47. Gerlach J. New anti psychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17: 298–309

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Toronto, The Wellesley Hospital, Toronto, Ontario, Canada

    A. George Awad, Lakshmi N. P. Voruganti & Ronald J. Heslegrave

Authors
  1. A. George Awad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lakshmi N. P. Voruganti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald J. Heslegrave
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Awad, A.G., Voruganti, L.N.P. & Heslegrave, R.J. The Aims of Antipsychotic Medication. CNS Drugs 4, 8–16 (1995). https://doi.org/10.2165/00023210-199504010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199504010-00002

Keywords

Search

Navigation